Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 29 points (-0.2%) at 16,918 as of Monday, June 23, 2014, 1:00 PM ET. The NYSE advances/declines ratio sits at 1,480 issues advancing vs. 1,509 declining with 147 unchanged. The Health Care sector currently sits down 0.2% versus the S&P 500, which is down 0.1%. Top gainers within the sector include AbbVie ( ABBV), up 1.1%, and Medtronic ( MDT), up 0.6%. On the negative front, top decliners within the sector include Regeneron Pharmaceuticals ( REGN), down 3.0%, Alexion Pharmaceuticals ( ALXN), down 2.1%, Grifols ( GRFS), down 1.9%, Smith & Nephew ( SNN), down 1.8% and Novo Nordisk A/S ( NVO), down 1.3%. TheStreet would like to highlight 3 stocks pushing the sector higher today: 3. Forest Laboratories ( FRX) is one of the companies pushing the Health Care sector higher today. As of noon trading, Forest Laboratories is up $2.29 (2.4%) to $99.16 on light volume. Thus far, 802,997 shares of Forest Laboratories exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $97.86-$99.45 after having opened the day at $98.16 as compared to the previous trading day's close of $96.87. Forest Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and sells branded forms of ethical drug products in the United States and Europe. Forest Laboratories has a market cap of $26.4 billion and is part of the drugs industry. Shares are up 61.4% year-to-date as of the close of trading on Friday. Currently there are 4 analysts who rate Forest Laboratories a buy, no analysts rate it a sell, and 13 rate it a hold. TheStreet Ratings rates Forest Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, good cash flow from operations and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Forest Laboratories Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.